Signaling Pathways Involved in Liver Cancer Development and Progression

Dear Colleagues,

Signaling pathways play an essential role in cancer development and progression. Most pathways result in deregulation in tumor cells, triggering a proliferative and aggressive phenotype. Several pathways have been linked to liver tumor progression, as PI3K/AKT, MAPKs, TGF β, Notch, Wnt/β-catenin, Hippo and apoptotic signaling. Signaling proteins and soluble factors/receptors that modulate these pathways are potential targets for therapeutic treatments. To date, only a limited number of drugs have successfully been employed in liver cancer therapies, for different reasons, including the high heterogeneity of tumors and a still limited knowledge of signaling cascades and their crosstalk. Nevertheless, as research goes on, new findings are emerging, and novel drugs developed. At present, a number of clinical trials have been conducting for testing agents that act on growth factor receptors and intracellular signaling pathways.

Thus, it could be useful to provide insight into the molecular mechanisms leading to liver development and progression, and eventually, potential therapeutic treatments for patients affected by liver cancer.

Dr. Alessandra Gentilini
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.